Leha, Andreas

[["dc.bibliographiccitation.firstpage","e0224453"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Hellenkamp, Kristian"],["dc.contributor.author","Unsöld, Bernhard"],["dc.contributor.author","Mushemi-Blake, Sitali"],["dc.contributor.author","Shah, Ajay M."],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Seidler, Tim"],["dc.contributor.editor","Ehrman, Robert"],["dc.date.accessioned","2020-12-10T18:42:11Z"],["dc.date.available","2020-12-10T18:42:11Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1371/journal.pone.0224453"],["dc.identifier.eissn","1932-6203"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16598"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77837"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","A machine learning approach for the prediction of pulmonary hypertension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Beißbarth, Tim"],["dc.date.accessioned","2020-03-27T13:37:27Z"],["dc.date.available","2020-03-27T13:37:27Z"],["dc.date.issued","2011"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/63393"],["dc.title","The Emacs Org-mode: Reproducible Research and Beyond"],["dc.type","report"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","9"],["dc.bibliographiccitation.lastpage","100"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Beißbarth, Tim"],["dc.date.accessioned","2020-04-02T10:43:45Z"],["dc.date.available","2020-04-02T10:43:45Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.4230/OASIcs.GCB.2013.90"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/63516"],["dc.relation.eisbn","978-3-939897-59-0"],["dc.relation.eventlocation","Dagstuhl"],["dc.relation.eventstart","2013"],["dc.relation.ispartof","German Conference on Bioinformatics 2013"],["dc.title","Utilization of ordinal response structures in classification with high-dimensional expression data"],["dc.type","conference_paper"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","JBMR Plus"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Wilde, Deborah"],["dc.contributor.author","Wilken, Lara"],["dc.contributor.author","Stamm, Bettina"],["dc.contributor.author","Blaschke, Martina"],["dc.contributor.author","Heppner, Christina"],["dc.contributor.author","Chavanon, Mira‐Lynn"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Herrmann‐Lingen, Christoph"],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2021-06-01T10:50:47Z"],["dc.date.available","2021-06-01T10:50:47Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/jbm4.10245"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17136"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86788"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2473-4039"],["dc.relation.issn","2473-4039"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The HPQ—Development and First Administration of a Questionnaire for Hypoparathyroid Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Pharmacology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Götz, Marcus R."],["dc.contributor.author","Collado, Juan A."],["dc.contributor.author","Fernández-Ruiz, Javier"],["dc.contributor.author","Fiebich, Bernd L."],["dc.contributor.author","García-Toscano, Laura"],["dc.contributor.author","Gómez-Cañas, María"],["dc.contributor.author","Koch, Oskar"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Muñoz, Eduardo"],["dc.contributor.author","Navarrete, Carmen"],["dc.contributor.author","Pazos, Maria R."],["dc.contributor.author","Holzgrabe, Ulrike"],["dc.date.accessioned","2020-12-10T18:44:36Z"],["dc.date.available","2020-12-10T18:44:36Z"],["dc.date.issued","2019"],["dc.description.abstract","Background: As a library of cannabinoid (CB) derivatives with (-)-trans-cannabidiol (CBD) or (-)-trans-cannabidivarin (CBDV) scaffold, we synthesized nine novel cannabinoids: 2-hydroxyethyl cannabidiolate (2-HEC), 2-hydroxypentyl cannabidiolate (2-HPC), 2,3-dihydroxypropyl cannabidiolate (GCBD), cyclohexyl cannabidiolate (CHC), n-hexyl-cannabidiolate (HC), 2-(methylsulfonamido)ethyl cannabidiolate (NMSC), 2-hydroxyethyl cannabidivarinolate (2-HECBDV), cyclohexyl cannabidivarinolate (CHCBDV), and n-hexyl cannabidivarinolate (HCBDV). Their binding and intrinsic effects at the CB1- and CB2-receptors and the effects on inflammatory signaling cascades were investigated in in vitro and ex vivo cell models. Materials and Methods: Binding affinity was studied in membranes isolated from CB-receptor-transfected HEK293EBNA cells, intrinsic functional activity in Chinese hamster ovary (CHO) cells, and activation of nuclear factor κB (NF-κB) and nuclear factor of activated T-cells (NFAT) in phorbol 12-myristate 13-acetate (PMA)/ionomycin (IO)-treated Jurkat T-cells. Inhibition of interleukin (IL)-17-induced pro-inflammatory cytokines and chemokines [IL-6, IL-1β, CC-chemokine ligand 2 (CCL2), and tumor necrosis factor (TNF)-α] was studied in RAW264.7 macrophages at the RNA level. Pro-inflammatory cytokine (IL-1β, IL-6, IL-8, and TNF-α) expression and prostaglandin E2 (PGE2) expression were investigated at the protein level in lipopolysaccharide (LPS)-treated primary human monocytes. Results: Derivatives with long aliphatic side chains at the ester position at R1 [HC (5)] as well as the ones with polar side chains [2-HECBDV (7), NMSC (6), and 2-HEC (1)] can be selective for CB2-receptors. The CBDV-derivatives HCBDV and CHCBDV demonstrated specific binding at CB1- and CB2-receptors at nanomolar concentrations. 2-HEC, 2-HPC, GCBD, and NMSC were agonists at CB2-receptor and antagonists at CB1-receptor. CHC bound both receptors at submicromolar ranges and was an agonist for these receptors. 2-HECBDV was an agonist at CB2-receptor and an antagonist at the CB1-receptor despite its modest affinity at this receptor (micromolar range). NMSC inhibited NF-κB and NFAT activity, and 2-HEC, 2-HPC, and GCBD dose-dependently inhibited PMA/IO-stimulated NFAT activation. CHC and HC dose-dependently reduced IL-1β and CCL2 messenger RNA (mRNA) expression. NMSC inhibited IL-1β, CCL2, and TNF-α at lower doses. At higher doses, it induced a pronounced increase in IL-6 mRNA. 2-HEC, 2-HPC, and GCBD dose-dependently inhibited LPS-induced IL-1β, TNF-α, and IL-6 synthesis. NMSC further increased LPS-stimulated IL-1β release but inhibited IL-8, TNF-α, and PGE2. Conclusion: The CBD- and CBDV-derivatives studied are suitable for targeting CB-receptors. Some may be used as selective CB2 agonists. The length of the aliphatic rest at R2 of CBD (pentyl) and CBDV (propyl) did not correlate with the binding affinity. Higher polarity at R1 appeared to favor the agonistic activity at CB2-receptors."],["dc.identifier.doi","10.3389/fphar.2019.01284"],["dc.identifier.eissn","1663-9812"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17061"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78525"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1663-9812"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Structure–Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","57"],["dc.bibliographiccitation.issue","01"],["dc.bibliographiccitation.journal","Klinische Monatsblätter für Augenheilkunde"],["dc.bibliographiccitation.lastpage","63"],["dc.bibliographiccitation.volume","239"],["dc.contributor.author","Schittkowski, Michael P."],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Horn, Maren"],["dc.contributor.author","Naxer, Sabine"],["dc.date.accessioned","2022-04-01T10:02:44Z"],["dc.date.available","2022-04-01T10:02:44Z"],["dc.date.issued","2022"],["dc.description.abstract","Zusammenfassung Hintergrund Darstellung der klinischen Befunde der ableitenden Tränenwege bei Patienten mit kongenitalem klinischen Anophthalmus und funktionslosem Mikrophthalmus (MAC-Komplex). Methoden Retrospektive Studie von 207 konsekutiven Patienten, die zwischen 1998 und 2021 mindestens einmal mit hochhydrophilen selbstquellenden Expandern bei MAC operiert wurden. Das Tränenwegssystem wurde in Vollnarkose immer vor allen anderen operativen Maßnahmen sondiert und gespült. Ergebnisse 64 Patienten wurden wegen möglicher Fehldiagnosen aufgrund vorheriger Lid- oder Orbitachirurgie an anderer Stelle oder wegen fehlender Daten ausgeschlossen. Die Analyse umfasste daher 67 Mädchen und 76 Jungen im Alter zwischen 1 und 126 Monaten (medianes Alter: 5 Monate). 72 Patienten wiesen einen unilateralen und 42 einen bilateralen Anophthalmus auf, 24 einen unilateralen und 5 einen bilateralen Mikrophthalmus; somit standen 286 Augenhöhlen (davon 190 mit Pathologie) zur Beurteilung zur Verfügung. Bei einseitigen Fällen war das Tränenwegssystem auf der normalen Seite nie betroffen. Auf der anophthalmischen oder mikrophthalmischen Seite war das Tränenwegssystem nur in 68 Augenhöhlen (35,8%) unauffällig. Der häufigste Befund war eine Kanalikulusstenose (91 Augenhöhlen; 48%). Eine Stenose des Canaliculus communis wurde in 12 Augenhöhlen (6,3%) und eine Obstruktion des Ductus nasolacrimalis in 9 Augenhöhlen (4,7%) festgestellt. Es gab 4 Fälle von Aplasie beider Tränenpünktchen, andere Anomalien waren nicht auffällig. Beim einseitigen Anophthalmus ließ sich bei pathologischen Befunden der Tränenwegssondierung ein signifikanter Zusammenhang mit einer Lippen-Kiefer-Gaumen-Spalte feststellen, was in den 3 anderen Gruppen nicht der Fall war. Schlussfolgerungen Beim kongenitalen klinischen Anophthalmus ist das Tränensystem in bis zu 66,5% der Fälle betroffen, meist aufgrund einer Kanalikulusstenose. Auch wenn es keine eindeutigen Hinweise auf einen embryologischen Zusammenhang gibt, ist diese Assoziation sicher kein Zufallsbefund."],["dc.identifier.doi","10.1055/a-1721-2375"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105993"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1439-3999"],["dc.relation.issn","0023-2165"],["dc.title","Tränenwegsbefunde von 143 Kindern mit Mikrophthalmus-Anophthalmus-Komplex"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3010"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Delonge, Laura M."],["dc.contributor.author","Haack, Anna-Maria"],["dc.contributor.author","Shuch, Brian"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2021-04-14T08:31:08Z"],["dc.date.available","2021-04-14T08:31:08Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12103010"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83497"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Experimental and Clinical Endocrinology & Diabetes"],["dc.contributor.author","Witzel, Judith Charlotte"],["dc.contributor.author","Giessel, Anna"],["dc.contributor.author","Heppner, Christina"],["dc.contributor.author","Lamersdorf, Annette"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Glueer, Claus"],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2022-12-01T08:31:03Z"],["dc.date.available","2022-12-01T08:31:03Z"],["dc.description.abstract","Introduction: Established scores estimate 10-year fracture risk in osteoporosis to assist with treatment recommendations. This study compares and contrasts the risk probabilities of major osteoporotic and hip fractures calculated by the FRAX tool with those of the DVO score, established in German-speaking countries.\nMaterial and methods: This seven-year retrospective study analyzes data of 125 male patients (mean age: 59.2±10.7 years) evaluated for osteoporosis. For the DVO score, the therapy threshold of >30% for vertebral and hip fractures suggested by DVO guidelines was implemented. We calculated fracture risks based on FRAX scores with aBMD and applied a common therapy threshold of ≥3% for hip fracture and subsequently determined the “DVO-equivalent risk level” for FRAX-based assessment that would identify as many male patients as identified by the DVO score. \nResults: Based on DVO score, 60.0% of patients had a 10-year risk of hip and vertebral fractures >30%. The recommendations for individuals based on FRAX scores for hip fracture with aBMD with risk ≥ 3% overlapped with those based on DVO score in 40.8% of patients. Patients identified for treatment only by DVO score presented a higher percentage of spine fractures (65% vs. 41%). The thresholds for this “DVO-equivalent risk level” for ‘FRAX with aBMD’ would be ≥ 6.9% for MOF and ≥ 2.1% for HF.\nThis study demonstrates that the DVO score was more sensitive than the FRAX score for patients with spinal fractures. We suggest considering the appropriate score and therapy threshold carefully in the daily care of male patients."],["dc.identifier.doi","10.1055/a-1977-4413"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1439-3646"],["dc.relation.issn","0947-7349"],["dc.title","Discrepancies between osteoporotic fracture evaluations in men based on German (DVO) osteoporosis guidelines or the FRAX score"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","593"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Histopathology"],["dc.bibliographiccitation.lastpage","606"],["dc.bibliographiccitation.volume","78"],["dc.contributor.author","Fichtner, Alexander"],["dc.contributor.author","Richter, Annika"],["dc.contributor.author","Filmar, Simon"],["dc.contributor.author","Gaisa, Nadine T"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Reis, Henning"],["dc.contributor.author","Nettersheim, Daniel"],["dc.contributor.author","Oing, Christoph"],["dc.contributor.author","Gayer, Fabian A"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Küffer, Stefan"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Kaulfuß, Silke"],["dc.contributor.author","Bremmer, Felix"],["dc.date.accessioned","2021-04-14T08:23:39Z"],["dc.date.available","2021-04-14T08:23:39Z"],["dc.date.issued","2020"],["dc.description.abstract","Aims Malignant germ cell tumours (GCTs) of the testis are rare neoplasms, but the most common solid malignancies in young men. World Health Organization guidelines divide GCTs into five types, for which numerous immunohistochemical markers allow exact histological subtyping in the majority of cases. In contrast, a germ cell origin is often hard to prove in metastatic GCTs that have developed so‐called somatic malignant transformation. A high percentage, up to 89%, of GCTs are characterised by the appearance of isochromosome 12p [i(12p)]. Fluorescence in‐situ hybridisation has been the most common diagnostic method for the detection of i(12p) so far, but has the disadvantages of being time‐consuming, demanding, and not being a stand‐alone method. The aim of the present study was to establish a quantitative real‐time polymerase chain reaction assay as an independent method for detecting i(12p) and regional amplifications of the short arm of chromosome 12 by using DNA extracted from formalin‐fixed paraffin‐embedded tissue. Methods and results A cut‐off value to distinguish between the presence and absence of i(12p) was established in a control set consisting of 36 tumour‐free samples. In a training set of 149 GCT samples, i(12p) was detectable in 133 tumours (89%), but not in 16 tumours (11%). In a test set containing 27 primary and metastatic GCTs, all 16 tumours with metastatic spread and/or somatic malignant transformation were successfully identified by the detection of i(12p). Conclusion In summary, the qPCR assay presented here can help to identify, further characterise and assign a large proportion of histologically inconclusive malignancies to a GCT origin."],["dc.description.sponsorship","Wilhelm Sander‐Stiftung http://dx.doi.org/10.13039/100008672"],["dc.identifier.doi","10.1111/his.14258"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81003"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1365-2559"],["dc.relation.issn","0309-0167"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real‐time polymerase chain reaction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","127"],["dc.bibliographiccitation.journal","BMC Bioinformatics"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Jung, Klaus"],["dc.date.accessioned","2018-11-07T08:56:54Z"],["dc.date.available","2018-11-07T08:56:54Z"],["dc.date.issued","2011"],["dc.description.abstract","Background: Discovery of biomarkers that are correlated with therapy response and thus with survival is an important goal of medical research on severe diseases, e. g. cancer. Frequently, microarray studies are performed to identify genes of which the expression levels in pretherapeutic tissue samples are correlated to survival times of patients. Typically, such a study can take several years until the full planned sample size is available. Therefore, interim analyses are desirable, offering the possibility of stopping the study earlier, or of performing additional laboratory experiments to validate the role of the detected genes. While many methods correcting the multiple testing bias introduced by interim analyses have been proposed for studies of one single feature, there are still open questions about interim analyses of multiple features, particularly of high-dimensional microarray data, where the number of features clearly exceeds the number of samples. Therefore, we examine false discovery rates and power rates in microarray experiments performed during interim analyses of survival studies. In addition, the early stopping based on interim results of such studies is evaluated. As stop criterion we employ the achieved average power rate, i.e. the proportion of detected true positives, for which a new estimator is derived and compared to existing estimators. Results: In a simulation study, pre-specified levels of the false discovery rate are maintained in each interim analysis, where reduced levels as used in classical group sequential designs of one single feature are not necessary. Average power rates increase with each interim analysis, and many studies can be stopped prior to their planned end when a certain pre-specified power rate is achieved. The new estimator for the power rate slightly deviates from the true power rate but is comparable to other estimators. Conclusions: Interim analyses of microarray experiments can provide evidence for early stopping of long-term survival studies. The developed simulation framework, which we also offer as a new R package 'SurvGenesInterim' available at http://survgenesinter.R-Forge.R-Project.org, can be used for sample size planning of the evaluated study design."],["dc.identifier.doi","10.1186/1471-2105-12-127"],["dc.identifier.isi","000290784600001"],["dc.identifier.pmid","21527044"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6343"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23260"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2105"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Sequential interim analyses of survival data in DNA microarray experiments"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]